Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
MariMed Inc. reports news on its multi-state cannabis operating platform, including cultivation, production, branded consumer products and retail dispensaries. Company updates commonly cover financial results, earnings-call schedules, wholesale distribution, branded product activity and retail operations tied to names such as Betty's Eddies, Bubby’s Baked, InHouse, Nature’s Heritage, Vibations and Thrive Dispensary.
Recurring developments also include capital-structure actions, preferred-stock obligations, hemp-derived THC product launches, cannabis regulatory commentary and community initiatives associated with the company's dispensary and brand portfolio.
MariMed, Inc. (CSE: MRMD) reported third-quarter financial results for the period ending September 30, 2022, highlighting a revenue increase to $33.9 million from $33.2 million year-over-year. The gross margin declined to 48% from 55%, while GAAP net income rose to $2.7 million from $2.1 million. Non-GAAP Adjusted EBITDA fell to $8.6 million versus $12.6 million the prior year. The company revised its 2022 revenue guidance to $132-$135 million, reflecting regulatory delays.
MariMed has announced the evolution of its popular Betty’s Eddies cannabis fruit chews, enhancing their formulations to cater to consumer needs for sleep, pain relief, stress relief, and more. Incorporating full-spectrum cannabis and natural ingredients, the new product lineup includes flavors like Bedtime Betty’s, Ache Away Eddies, and Go Betty Go, among others. These changes reflect the company's commitment to meet the growing demands of cannabis consumers. The updated products will be available in select states including Massachusetts, Maryland, Maine, and Delaware.
MariMed, a multi-state cannabis operator, will report its Q3 2022 financial results on November 7, 2022, after market close. A conference call is scheduled for November 8, 2022, at 8:00 a.m. EST to discuss these results. Investors can access the earnings webcast on MariMed's Investor Relations website. The company is known for its high-quality cannabis products, including award-winning brands like Betty's Eddies and Nature’s Heritage. MariMed is dedicated to improving lives through excellence in cannabis cultivation and product development.
MariMed, Inc. (CSE: MRMD), a prominent multi-state cannabis operator, has launched its first dispensary in Maryland, named Panacea Wellness, located in Annapolis. This 5,000 sq. ft. facility showcases MariMed's full range of award-winning products, including Nature’s Heritage and Betty’s Eddies. A grand opening event is scheduled for October 18, 2022, featuring local officials and community leaders. With this expansion, MariMed solidifies its vertical operations in Maryland, supported by a robust cultivation facility in Hagerstown. The Maryland market saw over $550 million in medical cannabis sales in 2021.
MariMed (CSE: MRMD) has announced a licensing agreement with 42 Degrees, a licensed cannabis producer in Michigan, to manufacture and distribute its brands, starting with the Betty’s Eddies full-spectrum fruit chews. This partnership aims to penetrate Michigan's rapidly growing cannabis market, which reported $1.8 billion in sales in 2021. The deal is aligned with MariMed's strategic growth plan, anticipating further product rollouts in 2023. Michigan's adult-use market is projected to reach $2.1 billion by 2025, representing significant growth potential for MariMed.
MariMed, Inc. (CSE: MRMD, OTCQX: MRMD) has announced its entry into Missouri's medical cannabis market with a new agreement to develop a production kitchen. The facility is expected to be completed in Q1 2023, allowing wholesale sales to start thereafter. The company plans to distribute its award-winning brands, including Betty's Eddies and Bubby's Baked. Missouri's medical cannabis sales are projected to hit $400 million in 2023, bolstered by anticipated voter approval for adult-use sales this November.
MariMed, a prominent multi-state cannabis operator, has appointed Jon Levine as President, effective immediately. Levine co-founded the company and has served in key financial roles, contributing to its robust financial performance. CEO Bob Fireman highlighted Levine's role in daily management and support in capital markets, allowing Fireman to focus on strategic growth. The company is poised for expansion amidst industry consolidation, backed by strong leadership and a solid balance sheet. MariMed aims to leverage new opportunities in the evolving cannabis landscape.
MariMed, a leading multi-state cannabis operator, has launched Nature’s Heritage 'LIVE Flower' in Massachusetts. This premium cannabis flower, enhanced through the proprietary FreshCure curing process, ensures peak freshness and vibrant characteristics. The product will initially be available at the Panacea Wellness dispensary and 25 select locations in Massachusetts, with plans for expansion to Delaware, Illinois, and Maryland. This innovative approach eliminates 2-3 weeks of drying time, delivering a smoother smoke and significant freshness.
MariMed, a multi-state cannabis operator, has announced its Nature’s Heritage brand as a Presenting Sponsor of the Cultivators Cup, set for September 3-4, 2022, in Worcester, MA. This event celebrates cannabis culture and recognizes top cultivators and brands in Massachusetts. Nature’s Heritage, a leading brand in the state, will be nominated in various categories. Attendees can enjoy music, food, and cannabis consumption, highlighting the company's role in the local cannabis community.
MariMed, Inc. (CSE: MRMD, OTCQX: MRMD) announced its Q2 financial results for 2022, reporting a revenue of $33.0 million, a slight increase from $32.6 million in Q2 2021. The company faced challenges with a gross margin of 45%, down from 60% YoY, and a GAAP net income of $1.9 million, decreasing from $7.6 million. Non-GAAP Adjusted EBITDA was $8.9 million, down from $13.9 million, with a margin of 27%. The revised 2022 revenue guidance is $135 million to $140 million, lower than the previous estimate of $145 million to $150 million. MariMed expanded its operational footprint with several acquisitions and product launches.